Literature DB >> 12842959

Strategy for randomised clinical trials in rare cancers.

Say-Beng Tan1, Keith B G Dear, Paolo Bruzzi, David Machin.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12842959      PMCID： PMC1126386          DOI： 10.1136/bmj.327.7405.47

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  13 in total

Review 1.  Methods in health service research. An introduction to bayesian methods in health technology assessment.

Authors:  D J Spiegelhalter; J P Myles; D R Jones; K R Abrams
Journal:  BMJ       Date:  1999-08-21

2.  Underpowered studies.

Authors:  R Lilford; A J Stevens
Journal:  Br J Surg       Date:  2002-02       Impact factor: 6.939

3.  Following a trial that stopped early: what next for adjuvant hepatic intra-arterial iodine-131 lipiodol in resectable hepatocellular carcinoma?

Authors:  S B Tan; D Machin; Y B Cheung; Y F A Chung; B C Tai; D Machin
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

4.  Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma.

Authors:  Say-Beng Tan; Y-F Alexander Chung; Bee-Choo Tai; Yin-Bun Cheung; David Machin
Journal:  Control Clin Trials       Date:  2003-04

5.  Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Authors:  A R Jadad; R A Moore; D Carroll; C Jenkinson; D J Reynolds; D J Gavaghan; H J McQuay
Journal:  Control Clin Trials       Date:  1996-02

6.  Clinical trials and rare diseases: a way out of a conundrum.

Authors:  R J Lilford; J G Thornton; D Braunholtz
Journal:  BMJ       Date:  1995-12-16

7.  The what, why and how of Bayesian clinical trials monitoring.

Authors:  L S Freedman; D J Spiegelhalter; M K Parmar
Journal:  Stat Med       Date:  1994 Jul 15-30       Impact factor: 2.373

8.  Monitoring of large randomised clinical trials: a new approach with Bayesian methods.

Authors:  M K Parmar; G O Griffiths; D J Spiegelhalter; R L Souhami; D G Altman; E van der Scheuren
Journal:  Lancet       Date:  2001-08-04       Impact factor: 79.321

Review 9.  Over-the-counter cold medications. A critical review of clinical trials between 1950 and 1991.

Authors:  M B Smith; W Feldman
Journal:  JAMA       Date:  1993-05-05       Impact factor: 56.272

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640
View more
  18 in total

Review 1.  Good-quality research in rare diseases: trials and tribulations.

Authors:  Davide Bolignano; Anna Pisano
Journal:  Pediatr Nephrol       Date:  2016-01-27       Impact factor: 3.714

2.  Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.

Authors:  Janne A Martikainen; Akseli Kivioja; Taru Hallinen; Pia Vihinen
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Emerging Opportunities for Target Discovery in Rare Cancers.

Authors:  Tanaz Sharifnia; Andrew L Hong; Corrie A Painter; Jesse S Boehm
Journal:  Cell Chem Biol       Date:  2017-09-21       Impact factor: 8.116

4.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.

Authors:  A F Leary; M Quinn; K Fujiwara; R L Coleman; E Kohn; T Sugiyama; R Glasspool; I Ray-Coquard; N Colombo; M Bacon; A Zeimet; A Westermann; E Gomez-Garcia; D Provencher; S Welch; W Small; D Millan; A Okamoto; G Stuart; K Ochiai
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

5.  The End-of-Life Experience of Patients With Rare Cancers and Their Caregivers.

Authors:  Elizabeth Trice Loggers; Holly G Prigerson
Journal:  Rare Tumors       Date:  2014-03-24

Review 6.  Innovative research methods for studying treatments for rare diseases: methodological review.

Authors:  Joshua J Gagne; Lauren Thompson; Kelly O'Keefe; Aaron S Kesselheim
Journal:  BMJ       Date:  2014-11-24

7.  Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.

Authors:  Aleksandar Sekulic; Winnie S Liang; Waibhav Tembe; Tyler Izatt; Semyon Kruglyak; Jeffrey A Kiefer; Lori Cuyugan; Victoria Zismann; Christophe Legendre; Mark R Pittelkow; John J Gohmann; Fernando R De Castro; Jeffrey Trent; John Carpten; David W Craig; Timothy K McDaniel
Journal:  Mol Genet Genomic Med       Date:  2014-11-27       Impact factor: 2.183

8.  Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper.

Authors:  P G Casali; P Bruzzi; J Bogaerts; J-Y Blay
Journal:  Ann Oncol       Date:  2014-10-01       Impact factor: 32.976

9.  Descriptive epidemiological study of rare, less common and common cancers in Western Australia.

Authors:  Gemma A Bilkey; Richard W Trevithick; Emily P Coles; Jennifer Girschik; Kristen J Nowak
Journal:  BMC Cancer       Date:  2021-07-08       Impact factor: 4.430

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.